Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lidocaine/tetracaine topical cream - Crescita Therapeutics

Drug Profile

Lidocaine/tetracaine topical cream - Crescita Therapeutics

Alternative Names: Flexicaine; Pliaglis; S-Caine™ Peel; Tetracaine/lidocaine topical cream - Crescita Therapeutics

Latest Information Update: 15 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZARS
  • Developer Crescita Therapeutics; Galderma; Nuvo Research
  • Class Acetanilides; Aminobenzoic acids; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Procedural pain
  • Phase II Unspecified
  • Discontinued Postherpetic neuralgia

Most Recent Events

  • 08 May 2024 Juyou Biotechnology plans a clinical trial for Procedural pain (Prevention) in China (Topical)
  • 25 Oct 2023 Taro Pharmaceuticals delivers a notice to terminate the license agreement for Pliaglis® in the USA
  • 01 Jun 2023 Croma-Pharma intends to launch lidocaine/tetracaine topical cream in other countries including Germany, the United Kingdom, Ireland, Switzerland, Brazil, Romania, Belgium, the Netherlands, Luxembourg and Brazil in 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top